Single answer
Is Alnylam Pharmaceuticals Inc (ALNY) a buy or sell?
4starter turns market data into one clear verdict you can act on.
Create a free account to save tickers and track your signals.
Log in to turn on watchlist alerts.
Decision snapshot
Everything you need to act fast, in one glance.
What is the conclusion?
Right now our advanced algorithms say:
$1 invested is now $0.97 or -3.05%
(In 16 weeks 3 days 1 hour 32 minutes and 51 seconds .)
Do analysts agree?
We compare consensus targets with today's price.
Consensus target for Alnylam Pharmaceuticals Inc is $461.06, which is $135.37 (41.56%) above the current price today's price.
Low target: $351.00 | High target: $549.00
Latest analyst updates
Recent rating and price target changes for this stock.
Company snapshot
A quick overview of the business and its public profile.
Alnylam Pharmaceuticals Inc a biopharmaceutical company focuses on discovering developing and commercializing novel therapeutics based on ribonucleic acid interference The companys pipeline of investigational RNAi therapeutics focuses on genetic medicines cardiometabolic diseases hepatic infectious diseases and central nervous system CNSocular diseases Its marketed products include ONPATTRO patisiran a lipid complex injection for the treatment of the polyneuropathy of hereditary transthyretinmediated amyloidosis in adults GIVLAARI for the treatment of adults with acute hepatic porphyria AHP and OXLUMO lumasiran for the treatment of primary hyperoxaluria type 1 PH1 In addition the company is developing givosiran for the treatment of adolescent patients with AHP patisiran for the treatment of transthyretin amyloidosis or ATTR amyloidosis with cardiomyopathy cemdisiran to treat complementmediated diseases ALNAAT02 for the treatment of AAT deficiencyassociated liver disease ALNHBV02 to treat chronic HBV infection Zilebesiran to treat hypertension and ALNHSD to treat NASH Further it offers Fitusiran for the treatment of hemophilia and rare bleeding disorders Inclisiran to treat hypercholesterolemia lumasiran for the treatment of advanced PH1 and recurrent renal stones and vutrisiran for the treatment of ATTR amyloidosis which is in phase 3 clinical trial Alnylam Pharmaceuticals Inc has strategic collaborations with Regeneron Pharmaceuticals Inc to discover develop and commercialize RNAi therapeutics for a range of diseases by addressing therapeutic targets expressed in the eye and CNS and Sanofi Genzyme to discover develop and commercialize RNAi therapeutics It also has license and collaboration agreements with Novartis AG Vir Biotechnology Inc Dicerna Pharmaceuticals Inc Ionis Pharmaceuticals Inc and PeptiDream Inc The company was founded in 2002 and is headquartered in Cambridge Massachusetts
Website: https://www.alnylam.com
Rates and inflation backdrop
US inflation for January 2026 was 0.17%. Over the last 12 months, inflation is 2.83%. The 10-year yield is 4.04 and is down -0.110 over the last 30 days.
Inflation sensitivity
Debt ratio: 0.26. Cash flow to debt ratio: 0.41. Net profit margin: 8.45%. Inflation risk score: low (0.40/1).
Dividend history check
We cannot find any recorded dividends paid in our systems.
Trading liquidity
Yes, the average daily trading liquidity for Alnylam Pharmaceuticals Inc is $545.4M. You should therefore be able to get in and out of your positions relatively fast.
10-year return check
On Alnylam Pharmaceuticals Inc, 2016-02-26 had a stock price of $58.00. If you invested back then, your return now would be a profit of $269.36 per share or 464.41%.
Why this answer
We combine price momentum, volatility, and trend signals to simplify the decision to one word.
Signal engine scans price, trend, and momentum indicators.
Targets and sentiment are checked against the live quote.
We keep the output simple: buy, sell, or hold.
Analyst consensus
How Wall Street targets compare to today's price.